株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

敗血症:パイプライン製品の分析

Sepsis - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 213120
出版日 ページ情報 英文 320 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
敗血症:パイプライン製品の分析 Sepsis - Pipeline Review, H1 2019
出版日: 2019年04月29日 ページ情報: 英文 320 Pages
概要

敗血症とは、細菌や他の微生物が侵入した際に人体が強く反応する、という疾患です。主な症状には、悪寒や震え、呼吸困難、血小板数の減少、心ポンプ機能の異常、腹痛などが含まれています。主な疾病素質には、年齢や免疫系の弱化などがあります。主な治療薬として、抗生物質や昇圧薬などが挙げられます。

当レポートでは、世界各国での敗血症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

敗血症の概要

治療薬の開発

  • 敗血症向けパイプライン製品:概要
  • 敗血症向けパイプライン製品:比較分析

各企業で開発中の敗血症治療薬

大学/研究機関で研究中の敗血症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

敗血症治療薬:開発中の製品の一覧(企業別)

敗血症治療薬:研究中の製品の一覧(大学/研究機関別)

敗血症治療薬の開発に従事している企業

  • Adrenomed AG
  • Altor BioScience Corporation
  • Am-Pharma B.V.
  • Arch Biopartners, Inc.
  • Aridis Pharmaceuticals LLC
  • 旭化成ファーマ
  • アステラス製薬
  • Batu Biologics, Inc.
  • Biomedica Management Corporation
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cell2B S.A.
  • Chiesi Farmaceutici SpA
  • Chiome Bioscience, Inc.
  • Cilian AG
  • Cognosci, Inc.
  • Cytheris SA
  • Endacea, Inc.
  • Evec, Inc.
  • Huons Co., Ltd.
  • Immune Response BioPharma, Inc.
  • Immunethep, SA
  • ImmunNovative Developments SL
  • InflaRx GmbH
  • Inotrem S.A.
  • Integrated BioTherapeutics, Inc.
  • Lead Discovery Center GmbH
  • Merck & Co., Inc.
  • Navigen Pharmaceuticals, Inc.
  • OncoImmune, Inc.
  • Opsona Therapeutics Limited
  • Orion Oyj
  • ProThera Biologics, LLC.
  • Ra Pharmaceuticals, Inc.
  • Recce Pty Ltd
  • Ribomic Inc.
  • 塩野義製薬
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Stemedica Cell Technologies, Inc.
  • Syntiron LLC
  • TaiRx, Inc.
  • 武田薬品工業
  • Therakind Limited
  • Therashock, LLC
  • TiGenix NV
  • VBS Pharmaceuticals
  • ViiV Healthcare Limited
  • XImmune AB

敗血症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

敗血症治療薬:開発が休止状態の製品

敗血症治療薬:開発が中止された製品

敗血症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Sepsis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Target, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Sepsis - Pipeline by Adrenomed AG, H1 2019
  • Sepsis - Pipeline by Am-Pharma BV, H1 2019
  • Sepsis - Pipeline by Arch Biopartners Inc, H1 2019
  • Sepsis - Pipeline by Asahi Kasei Pharma Corp, H1 2019
  • Sepsis - Pipeline by Atox Bio Ltd, H1 2019
  • Sepsis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2019
  • Sepsis - Pipeline by Boehringer Ingelheim GmbH, H1 2019
  • Sepsis - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Sepsis - Pipeline by Cell2B Advanced Therapeutics SA, H1 2019
  • Sepsis - Pipeline by Cells for Cells SA, H1 2019
  • Sepsis - Pipeline by China Grand Pharmaceutical and Healthcare Holdings Ltd, H1 2019
  • Sepsis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2019
  • Sepsis - Pipeline by Cilian AG, H1 2019
  • Sepsis - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by CytaCoat AB, H1 2019
  • Sepsis - Pipeline by Dr. Franz Kohler Chemie GmbH, H1 2019
  • Sepsis - Pipeline by Endacea Inc, H1 2019
  • Sepsis - Pipeline by Enlivex Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by Enzychem Lifesciences Corp, H1 2019
  • Sepsis - Pipeline by Evec Inc, H1 2019
  • Sepsis - Pipeline by Immunwork Inc, H1 2019
  • Sepsis - Pipeline by InflaRx NV, H1 2019
  • Sepsis - Pipeline by Integrated BioTherapeutics Inc, H1 2019
  • Sepsis - Pipeline by Lead Discovery Center GmbH, H1 2019
  • Sepsis - Pipeline by MetrioPharm AG, H1 2019
  • Sepsis - Pipeline by Microbiotix Inc, H1 2019
  • Sepsis - Pipeline by Mochida Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Nosopharm SAS, H1 2019
  • Sepsis - Pipeline by OncoImmune Inc, H1 2019
  • Sepsis - Pipeline by Ono Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Opsona Therapeutics Ltd, H1 2019
  • Sepsis - Pipeline by ProThera Biologics Inc, H1 2019
  • Sepsis - Pipeline by Q BioMed Inc, H1 2019
  • Sepsis - Pipeline by Ra Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by Recce Ltd, H1 2019
  • Sepsis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by Ribomic Inc, H1 2019
  • Sepsis - Pipeline by Rimonyx Pharmaceuticals Ltd, H1 2019
  • Sepsis - Pipeline by SciClone Pharmaceuticals Inc, H1 2019
  • Sepsis - Pipeline by SetLance srl, H1 2019
  • Sepsis - Pipeline by Shionogi & Co Ltd, H1 2019
  • Sepsis - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2019
  • Sepsis - Pipeline by Syntiron LLC, H1 2019
  • Sepsis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Sepsis - Pipeline by Therakind Ltd, H1 2019
  • Sepsis - Pipeline by Therashock LLC, H1 2019
  • Sepsis - Pipeline by Vascular BioSciences, H1 2019
  • Sepsis - Dormant Projects, H1 2019
  • Sepsis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Sepsis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Top 10 Routes of Administration, H1 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
目次
Product Code: GMDHC11067IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis - Pipeline Review, H1 2019, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 7, 1, 53, 6 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Sepsis - Overview
  • Sepsis - Therapeutics Development
  • Sepsis - Therapeutics Assessment
  • Sepsis - Companies Involved in Therapeutics Development
  • Sepsis - Drug Profiles
  • Sepsis - Dormant Projects
  • Sepsis - Discontinued Products
  • Sepsis - Product Development Milestones
  • Appendix
Back to Top